Advertisement
Australia markets close in 38 minutes

  • ALL ORDS

    7,803.60
    -95.30 (-1.21%)
     

  • ASX 200

    7,552.60
    -89.50 (-1.17%)
     

  • AUD/USD

    0.6399
    -0.0027 (-0.41%)
     

  • OIL

    84.63
    +1.90 (+2.30%)
     

  • GOLD

    2,398.40
    +0.40 (+0.02%)
     

  • Bitcoin AUD

    97,032.41
    +545.70 (+0.57%)
     

  • CMC Crypto 200

    1,284.63
    +399.09 (+43.74%)
     

  • AUD/EUR

    0.6015
    -0.0015 (-0.26%)
     

  • AUD/NZD

    1.0879
    +0.0004 (+0.04%)
     

  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     

  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     

  • FTSE

    7,877.05
    +29.06 (+0.37%)
     

  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     

  • DAX

    17,837.40
    +67.38 (+0.38%)
     

  • Hang Seng

    16,189.55
    -196.32 (-1.20%)
     

  • NIKKEI 225

    37,114.32
    -965.38 (-2.54%)
     

Iridex to Report Fourth Quarter and Full Year 2020 Financial Results on March 22, 2021

IRIDEX Corporation
·1-min read

MOUNTAIN VIEW, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the fourth quarter and full year of 2020 after the close of trading on Monday, March 22, 2021. The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET.

Investors interested in listening to the conference call may do so by dialing (844) 707-0665 for domestic callers or (703) 326-3030 for international callers, using conference ID: 1137827. A live and archived webcast of the event will be available on the “Investors” section of the Company’s website at: www.iridex.com.

About Iridex
Iridex is a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma, diabetic macular edema and other retinal diseases. Iridex products are sold in the United States and Germany through a direct sales force and in more than 100 countries through a network of independent distributors. For more information, visit www.iridex.com.

Investor Relations Contact:
Leigh Salvo
(415) 937-5404
investors@iridex.com

Media Contact:
Jamie Hall
Pascale Communications, LLC.
(724) 417-0167
pr@iridex.com